	Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON. Int J Urol Iwamoto H, Izumi K, Machioka K, Toriumi R, Shima T, Nozaki M, Hori T, Inaba T, Nakagawa R, Kamijima T, Kadomoto S, Makino T, Naito R, Yaegashi H, Shigehara K, Nohara T, Miyagi T, Seto C, Kadono Y, Mizokami A. PMID: 42639687 [PubMed - indexed for MEDLINE]
	Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice. J Multidiscip Healthc Jiang M, Chen Q, Chen X, Fu X, Chung SK. PMID: 42639254 [PubMed]
	Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities. Front Mol Biosci Fukiage Y, Okubo N, Taga M, Sato Y, Terada N. PMID: 42639050 [PubMed]
	Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes. Front Immunol Chen H, Lin Y, Xue Z, Qie Y, Wu Z, Liu K, Huang S, Jia K, Yang S, Zhang Z, Li P, Li X, Liu L, Shen C, Hu H. PMID: 42639047 [PubMed - indexed for MEDLINE]
	Beyond supplements and surrogates: an evidence-quality map informs a strategic rebalancing of dietary research in prostate cancer active surveillance. Front Nutr Li Y, Wang TQ, Zhu AY, Zhang YP, Fu Q. PMID: 42638961 [PubMed]
	A locally deployed large language model for pathology-informed and nurse-reviewed communication support in bladder cancer immunotherapy. Front Med (Lausanne) Diao S, Zhao J, Liu X. PMID: 42638714 [PubMed]
	Combination treatment with intravesical interferon-alpha gene therapy and an oral pan-ErbB receptor family blocker improves survival in mice with bladder cancer. Front Mol Biosci Sood A, Martini A, Genitiano P, Rauf M, Manyam G, Rudzinski JK, Tholomier C, Contieri R, Lee IL, Parker NR, Yla-Herttuala S, McConkey DJ, Dinney CPN, Mokkapati S. PMID: 42638663 [PubMed]
	Evaluation of AI-based segmentation and synthetic CT generation for MRI-only prostate radiotherapy planning. J Appl Clin Med Phys Östensson A, Jonsson J. PMID: 42638512 [PubMed - indexed for MEDLINE]
	A rule-based, feedback-driven framework for fully automated prostate VMAT planning. J Appl Clin Med Phys Sangster J, Taylor M, Jolly D, Gastaldo J, Lorenz F. PMID: 42638300 [PubMed - indexed for MEDLINE]
	Clinical impact of routine secondâ€‘opinion reading of [Â¹â¸F]FDGâ€‘PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network. Eur J Nucl Med Mol Imaging Lijnen RAG, Vierling ML, Ringia JB, Hendricksen K, KleinJan GH, Postema AW, Vogel WV, Boellaard TN, Braat AJAT, Heijmen L, van Rhijn BWG, Mertens LS. PMID: 42637974 [PubMed - as supplied by publisher]
	Metallic versus polymeric ureteric stents for chronic malignant ureteric obstruction: a systematic review and meta-analysis. World J Urol Lim QY, Kyaw L, Ong CSH, Law YXT, Tiong HY. PMID: 42637852 [PubMed - indexed for MEDLINE]
	Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications. Biochim Biophys Acta Rev Cancer Ren H, Li X, Jiang Z, Bai Y, Ai J. PMID: 42637058 [PubMed - as supplied by publisher]
	High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial. Lancet Oncol Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, Cozzi S, Benyoucef A, Hasbini A, Supiot S, Ronchin P, Wachter T, Azria D, Magne N, Zibouche M, Vial N, Cormier L. PMID: 42636837 [PubMed - indexed for MEDLINE]
	Nomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma. Clin Genitourin Cancer Menezes Jesus VL, Dos Anjos GC, Alves GKJ, Sandoval EAA, Barros GG, Cho DH, Lima FVS, de Carvalho PA, Gallucci FP, Cardili L, Pontes J Junior, Nahas WC, Cordeiro MD. PMID: 42636730 [PubMed - as supplied by publisher]
	Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians. JCO Oncol Pract Liyanage JSS, Ong V, Hamel LM, Eggly S, Carducci MA, Lansey DG, Heath EI, Moore TF, Albrecht TL, Manning MA, Kim S. PMID: 42636423 [PubMed - as supplied by publisher]
	Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer. J Natl Cancer Inst Noronha V, Menon N, Shah M, Patil V, Dhanawat A, Prakash G, Pal M, Arora A, Misra A, Goud S, More S, Yadav A, Murthy V, Maitre P, Menon S, Popat P, Sable N, Agarwal A, Rangarajan V, Shetake A, Badwe R, Prabhash K. PMID: 42636270 [PubMed - as supplied by publisher]
	A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. Cancer Res Commun Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI. PMID: 42636061 [PubMed - as supplied by publisher]
	A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer. Discov Oncol Handke A, Dellino M, Orf C, Wang N, Darr C, Bach P, Roghmann F, Tully KH. PMID: 42635876 [PubMed]
	Multimodal artificial intelligence in prostate cancer: integrating multiparametric MRI with clinicopathological, molecular, and functional imaging data. Abdom Radiol (NY) Fujiwara M, Yoshida S, Banerjee I, Arita Y, Fujii Y. PMID: 42635792 [PubMed - as supplied by publisher]
	Outcomes of [(177)Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study. Eur J Nucl Med Mol Imaging Arslan DF, Civan C, Sanli MO, Has Simsek D, Ekenel M, Basaran M, Erdem S, Ozcan F, Kuyumcu S, Sanli Y. PMID: 42635771 [PubMed - as supplied by publisher]

Articles 1 - 20 / 180945

Page 1 of 9048



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy